This review, therefore, aims to assess the IL-31/IL-33 axis in atopic dermatitis, highlight existing uncertainties, and emphasize the need to develop biomarker and endotype-based therapeutic strategies targeting this pathway. The gene discussed is IL33; the disease is atopic eczema.